-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 IwDGmc5/sxInX9rafsORwuepd1u7YCrNYI83DutzRXAmSGRegy1M0fX8bJiLU+wk
 tkVnpRBFk5KLQ/gBzuuxWg==

<SEC-DOCUMENT>0001188112-07-000981.txt : 20070404
<SEC-HEADER>0001188112-07-000981.hdr.sgml : 20070404
<ACCEPTANCE-DATETIME>20070404141050
ACCESSION NUMBER:		0001188112-07-000981
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20070330
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20070404
DATE AS OF CHANGE:		20070404

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			APPLIED DNA SCIENCES INC
		CENTRAL INDEX KEY:			0000744452
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				592262718
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	002-90539
		FILM NUMBER:		07748222

	BUSINESS ADDRESS:	
		STREET 1:		25 HEALTH SCIENCES DRIVE
		STREET 2:		SUITE 113
		CITY:			STONY BROOK
		STATE:			NY
		ZIP:			11790
		BUSINESS PHONE:		631 444 6861

	MAIL ADDRESS:	
		STREET 1:		25 HEALTH SCIENCES DRIVE
		STREET 2:		SUITE 113
		CITY:			STONY BROOK
		STATE:			NY
		ZIP:			11790

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PROHEALTH MEDICAL TECHNOLOGIES INC
		DATE OF NAME CHANGE:	20010504

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DCC ACQUISITION CORP
		DATE OF NAME CHANGE:	19990211

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DATALINK CAPITAL CORP/TX/
		DATE OF NAME CHANGE:	19980306
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>t13740_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<html>
  <head>
    <title>
      Form 8-K
</title>
<!-- Licensed to: Tri-State Financial-->
<!-- Document Created using EDGARizer HTML 3.0.4.0 -->
<!-- Copyright 2006 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</head>
  <body bgcolor="#ffffff"><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div>
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
      <hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>UNITED
      STATES</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>SECURITIES
      AND EXCHANGE COMMISSION</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>WASHINGTON,
      D.C. 20549</strong></font><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">
      <div>
        <hr style="COLOR: black" align="center" noshade size="1" width="10%">
      </div>
      <div>&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>FORM
      8-K</strong></font><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>CURRENT
      REPORT</strong></font><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>PURSUANT
      TO SECTION 13 OR 15(d) OF THE</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SECURITIES
      EXCHANGE ACT OF 1934</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">____________________</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Date
      of report (Date of earliest event reported): March 30,
      2007</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Applied
      DNA Sciences, Inc</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Exact
      Name of Registrant as Specified in Charter)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td valign="top" width="27%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Nevada</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(State
                or Other Jurisdiction</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">of
                Incorporation)</font></div>
            </td>
            <td valign="top" width="27%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>002-90539</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Commission
                File Number)</font></div>
            </td>
            <td valign="top" width="27%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>59-2262718</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(IRS
                Employer</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Identification
                No.)</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>25
      Health Sciences Drive, Suite 113</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Stony
      Brook, New York 11790</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address
      of Principal Executive Offices) (Zip Code)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>631-444-6861</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Registrant&#8217;s
      telephone number, including area code)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Not
      Applicable</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Former
      Name or Former Address, if Changed Since Last Report)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Check
      the
      appropriate box below if the Form 8-K filing is intended to simultaneously
      satisfy the filing obligation of the registrant under any of the following
      provisions (see General Instruction A.2 below):</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br>
      <div align="left">
        <table cellpadding="0" cellspacing="0" width="100%">

            <tr>
              <td align="justify" valign="top" width="3%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings"><font style="DISPLAY: inline; FONT-FAMILY: Wingdings">o</font></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              </td>
              <td align="justify" valign="top" width="97%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Written
                  communications pursuant to Rule 425 under the Securities Act (17
                  CFR
                  230.425)</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              </td>
            </tr>
            <tr>
              <td align="justify" valign="top" width="3%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings"><font style="DISPLAY: inline; FONT-FAMILY: Wingdings">o</font></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              </td>
              <td align="justify" valign="top" width="97%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Soliciting
                  material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
                  240.14a-12)</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              </td>
            </tr>
            <tr>
              <td align="justify" valign="top" width="3%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings"><font style="DISPLAY: inline; FONT-FAMILY: Wingdings">o</font></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              </td>
              <td align="justify" valign="top" width="97%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pre-commencement
                  communications pursuant to Rule 14d-2(b) under the Exchange Act
                  (17 CFR
                  240.14d-2(b))</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              </td>
            </tr>
            <tr>
              <td align="justify" valign="top" width="3%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings"><font style="DISPLAY: inline; FONT-FAMILY: Wingdings">o</font></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              </td>
              <td align="justify" valign="top" width="97%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pre-commencement
                  communications pursuant to Rule 13e-4(c) under the Exchange Act
                  (17 CFR
                  240.13e-4(c))</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              </td>
            </tr>

        </table>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: silver" noshade size="1">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Item
      8.01 </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Other
      Events.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On
      April
      4, 2007, Applied DNA Sciences, Inc. (the &#8220;Company&#8221;) issued a press release to
      announce that the parties to the Sub-License Agreement dated July 29, 2003,
      by
      and between the Company, Biowell Technology, Inc. and G.A. Corporate Finance
      Ltd., have terminated such Sub-License Agreement, and that in connection with
      such termination all of G.A. Corporate Finance Ltd.&#8217;s interests in Applied DNA
      Sciences Europe Ltd. have been transferred to the Company. A copy of the press
      release is attached as Exhibit 99.1 to this Current Report on Form
      8-K.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Item
      9.01 Financial Statements and Exhibits</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br>
      <div align="left">
        <table cellpadding="0" cellspacing="0" width="100%">

            <tr>
              <td align="left" valign="top" width="5%">&#160;</td>
              <td align="left" valign="top" width="6%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(d)
                  </font></div>
              </td>
              <td align="left" valign="top" width="89%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exhibits.</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div align="left">&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
      <div align="left">
        <table border="0" cellpadding="0" cellspacing="0" width="100%">

            <tr>
              <td width="5%">&#160;</td>
              <td align="left" valign="top" width="10%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exhibit
                  99.1</font></div>
              </td>
              <td align="left" valign="top" width="85%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Press
                  release of Applied DNA Sciences, Inc., dated April 4,
                  2007.</font></div>
              </td>
            </tr>

        </table>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 108pt; TEXT-INDENT: -72pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: silver" noshade size="1">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SIGNATURE</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
      to the requirements of the Securities Exchange Act of 1934, the registrant
      has
      duly caused this report to be signed on its behalf by the undersigned hereunto
      duly authorized.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br>
      <div>
        <table cellpadding="0" cellspacing="0" width="100%">

            <tr>
              <td align="left" valign="top" width="36%">&#160;</td>
              <td align="left" valign="top" width="38%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Applied
                  DNA Sciences, Inc.</strong></font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="36%">&#160;</td>
              <td align="left" valign="top" width="38%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Registrant)</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="36%">&#160;</td>
              <td align="left" valign="top" width="38%">&#160;</td>
            </tr>
            <tr>
              <td align="left" valign="top" width="36%">&#160;</td>
              <td align="left" valign="top" width="38%">&#160;</td>
            </tr>
            <tr>
              <td align="left" valign="top" width="36%">&#160;</td>
              <td align="left" valign="top" width="38%">&#160;</td>
            </tr>
            <tr>
              <td align="left" valign="top" width="36%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" valign="top" width="38%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">By:
                  </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>/s/
                  James
                  Hayward&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
                  </u></font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="36%">&#160;</td>
              <td align="left" valign="top" width="38%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">James
                  Hayward</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="36%">&#160;</td>
              <td align="left" valign="top" width="38%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Chief
                  Executive Officer</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="36%">&#160;</td>
              <td align="left" valign="top" width="38%">&#160;</td>
            </tr>
            <tr>
              <td align="left" valign="top" width="36%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date:
                  April 4, 2007</font></div>
              </td>
              <td align="left" valign="top" width="38%">&#160;</td>
            </tr>

        </table>
      </div>
    </div>
    <div>&#160;</div>
    <div>&#160;</div>
    <div>&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: silver" noshade size="1">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div>&#160;</div>
    <div>
      <div align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
        <div align="left">
          <table border="0" cellpadding="0" cellspacing="0" width="100%">

              <tr>
                <td width="10%"><u><font size="2">Exhibit No.</font></u></td>
                <td align="left" valign="top" width="5%" style="border-bottom: medium none;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                </td>
                <td align="left" valign="top" width="85%" style="border-bottom: medium none;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>Description
                    of Exhibit</u></font></div>
                </td>
              </tr>
              <tr>
                <td width="10%">&#160;</td>
                <td align="left" valign="top" width="5%">&#160;</td>
                <td align="left" valign="top" width="85%">&#160;</td>
              </tr>
              <tr>
                <td width="10%"><font size="2">99.1</font></td>
                <td align="left" valign="top" width="5%">&#160;</td>
                <td align="left" valign="top" width="85%"><font size="2">Press
                  Release of
                  Applied DNA Sciences, Inc., dated April 4,
                  2007.</font></td>
              </tr>

          </table>
        </div>
      </div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt"></font>&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
  </body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title>
    </title>
<!-- Licensed to: Tri-State Financial-->
<!-- Document Created using EDGARizer HTML 3.0.4.0 -->
<!-- Copyright 2006 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</head>
  <body bgcolor="#ffffff">
    <div>
      <hr style="COLOR: black" align="center" noshade size="1" width="100%">
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><img src="logo.jpg" alt=""></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;

      <div>
        <div>
          <div>
            <hr style="COLOR: black" align="center" noshade size="1" width="100%">
          </div>
        </div>&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Applied
      DNA Sciences Acquires Applied DNA Sciences Europe Ltd.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">STONY
      BROOK, N.Y., April 4, 2007 /Business Wirel/ -- Applied DNA Sciences, Inc. (OTC
      Bulletin Board: APDN), a DNA security solutions company, today announced that
      Applied DNA Sciences Europe Ltd., an English private limited company, is now
      a
      wholly owned subsidiary of Applied DNA Sciences, Inc. In July 2003, APDN,
      Biowell Technology, Inc. and G.A. Corporate Finance Ltd. entered into a
      Sub-License Agreement that provided G.A. Corporate Finance a license to market
      and sell APDN&#8217;s products in the U.K., among other things. G.A. Corporate Finance
      formed Applied DNA Sciences Europe Ltd. in April 2003 in anticipation of this
      agreement. On March 30, 2007, the parties terminated this agreement. All rights
      to market and sell APDN products in the U.K. were returned to APDN, and all
      of
      G.A. Corporate Finance&#8217;s interests in Applied DNA Sciences Europe Ltd. were
      transferred to APDN.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;As
      the
      company moves forward and continues to establish business relationships with
      not
      only U.S., but also European and other companies worldwide, we thought it was
      important to consolidate rights for our technologies and have direct control
      of
      our business in the U.S. and Europe,&#8220; stated Dr. James A. Hayward, CEO of
      Applied DNA Sciences. &#8220;We hope that this strategic move will position the
      company well for its next phase of growth and will allow APDN to maximize the
      opportunities we will have in the years ahead.&#8221;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>About
      Applied DNA Sciences, Inc.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Applied
      DNA Sciences, Inc. provides botanical DNA encryption, embedment and
      authentication solutions that can help protect companies, governments and
      consumers from counterfeiting, fraud, piracy, product diversion, identity theft
      and unauthorized intrusion into physical locations and databases. APDN&#8217;s common
      stock is listed on the Over-The-Counter Bulletin Board under the symbol "APDN".
      </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      statements made by APDN may be forward-looking in nature and are made pursuant
      to the safe harbor provisions of the Private Securities Litigation Reform Act
      of
      1995. Forward-looking statements describe APDN&#8217;s future plans, projections,
      strategies and expectations, and are based on assumptions and involve a number
      of risks and uncertainties, many of which are beyond the control of APDN. Actual
      results could differ materially from those projected due to our short operating
      history, limited market acceptance, market competition and various other factors
      detailed from time to time in APDN&#8217;s SEC reports and filings, including our
      Annual Report on Form 10-KSB, filed on January 16, 2007 and our subsequent
      quarterly report on Form 10-QSB. APDN undertakes no obligation to update
      publicly any forward-looking statements to reflect new information, events
      or
      circumstances after the date hereof to reflect the occurrence of unanticipated
      events.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SOURCE
      Applied DNA Sciences, Inc. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-0-03/2x/2007</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">/CONTACT:
      Debbie Bailey, 631-444-8090, fax: 631-444-8848/</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">/FCMN
      Contact: info@adnas.com /</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">/Web
      site: http://</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>www.ADNAS.com</u></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      /</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
  </body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<DESCRIPTION>APPLIED DNA SCIENCES LOGO
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`0$`2`!(``#_VP!#``8$!08%!`8&!08'!P8("A`*"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!#`0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P``1"`!?`7H#`2(``A$!`Q$!_\0`
M'0`!``(#`0$!`0````````````4&!`<(`P()`?_$`#X0``$#!``$`P<"!0(#
M"0````$"`P0`!081!Q(A,1-!410B,F%Q@9$(H146(T)2DK$S4]$7-F1R=8/#
MX?#_Q``;`0$``@,!`0```````````````0(#!`4&!__$`#(1``(!`P($`@H"
M`@,````````!`@,$$2$Q!1)!41.A!A0B,F%Q@9'!\%*QT?%"HK+_V@`,`P$`
M`A$#$0`_`.J:4I0"E*4`I2E`*4I0"E*4`I2E`*4I0"E*4`I2E`*4I0"E*4`I
M2E`*4I0"E*4`I2E`*4I0"E*4`I2E`0F6Y1:,3MAG7N6EAK>D)UM;A]$I'4FM
M.3_U'14R2(&/O.,`_$]("%$?0`Z_-:GXQ93(RG.)[RW%&)%<5&C-[Z)0DD;U
MZD]3_P#54BO<\/\`1V@J2G<K,GTSA+['%KW\W)JGHCL3`>,&/Y=*1!5XENN2
M_@9D$%+A]$K'0GY'1K9-?GHVM3:TK;44K204J!T0?6NT^#&3.Y5@,&;+45S&
M28SZSW4M&O>/S(*3]37*XYP:%DE6H^Z],=C:L[MUGR3W(_++E*>N[[)<6AII
M7*E`.A]:G,-NSBK?+]N<*FHP"@XKJ0.O3]JR\HMMG\%RXW:2B$VV/ZCZG`A.
MOGNJ4F\Q%0GVL?EB7:I74.*1HD@Z.B=;[=]5YWDER\V-.YOY6<=2YP<MARIJ
M6"TXT%JY4K5K1/EOTJQUJ*V>%_$8WCDI:\1/,1Z;K:LV;&A-AR4\AI)Z#F/?
MZ54DR*5CPIL:<V5Q'D.I'0\I[?6LB@%*4H!2E*`4I2@%*4H!2J;C^>,7?/+K
MBJK9+B3K>SXZUNJ04+3M(!3RD]PH&O3",W9RN[9!!9MLV&JT2?9U.2$Z2Z=J
M&T_Z=Z]"/6@+=2E*`4I50Q'.HN29'?+(W`FPYMH4$OA_D*222!RE*COM0%OI
M7Q(\4L.>SE`>Y3R%8)2%:Z;`ZZW6J,)S/-,KN-]AQV<=CNVB1[.Z7$/$+5M8
MVG2NWN'\UL4;:=:$III*.,Y^)CG54&D^IMJE:^GYO=,6N41C-K=%9M\MSPF[
MG!<4IE"SV#B5#:?KUJ3XF7V\8]C8NEA9@R5H=;;6U)"O>#BTH3RE)'7F4._E
M5O4ZG/&.GM;/.C^I'BQPWV+=2J)PHSLYG;I;=P8;AWJ"Z6Y45.P$]2`0"=^1
M!^8K,O5YOT7/+/:83=M5;)S:W5N.I7XJ`WKF`T==>8:Z?6HE:5(5949Z-?A9
M_H*K%Q4ULRWTKPN$E$*!)E.*2A#+2G%*5V``)V?ETK7G!;B#(SB'=$W-#+,^
M(\#X;0*1X2OAT#UZ$']JK"VJ3I2K17LQQGZDRJ1C)0>[-E4I2L!D%*4H!2E5
M'"<W9RN[Y!`:MLV&JT2/9U.2$Z2Z=J&T_P"G>O0B@+=2E*`4I2@%*4H!2E*`
M4/44I0'!V<6MZRY?=X$E*@XS)6!O^Y))(/W!!J#KL'B[PLBYPA,V$ZB)>FD<
MB75#W'4^25ZZ]/(C]ZY]G\(,XAR"U_!''P#H.,NH4D_O_O7T?AW&;>XHKGFH
MR6Z;P>?KVE2G)X644"NN_P!-UK>MO#1IQ])29TER4@'_`!(2D'[\F_O7.&6<
M/LDQ*!&FWN!X,=X\O,E86$*_Q5K8!-;OP[CK8V<.1_'&5L7.(E+0C16O=>`&
M@4>2>W4$C7E6MQWQ+RUBK5<Z;UQJ9++EI5&ZNCQU-6\<\TEY+F$R$EY0M=O>
M4PRR#[I4DZ4L^I)!U\JL?">]-2\;$)?N.0CRDGH"E1)!WZ]2*K6(8M$RVY72
M[R_%;@KE++3(5[QV2K2C\@1VJ4XA65%BPOV>S)\*&9`7(!)*E;[=?38'[5JW
MCM*L(<+AI)-:]$^OS?Y>YDH^+%NY>VIL$W6W,76!"E36VGI;Z&6TCWE;4=`Z
M]-U:<MB38LED3)"Y+?+I#A3H#U%<T<*;/(OG$&R1XZ5*#<E$AU0_M0A042?Q
MK[UVX\TV\@H>0EQ!_M4-BN%Q?AU/A\HTXRYFUE_@WK6XE73DUA%#P%#QNCJT
M;\`-D+/EOIK[U?Z^&66V$<C+:&T>B1H5]UR#:%*4H"HW$9A+R>4Q"=@6NPLL
M)4U+6T'W7W3W!3S#E2/IU]?2+P'-)]VR7(,7O:8@O%JY5HDQ0?"D-J[*Y224
MD;3L;/>J1B4YO,.)&5L9_.+:+6]X<*TOOEE@-[5_4*-@+.@.IWW^E8G"V;96
MOU`Y5_"U18UO>BH;B!`#:'2"@?T_)0)!T1WH"Q8)E.:Y9D&46@S[/$39I7@&
M4B"M2E]5`:07-#X=[)/IKSJ5Q_.+M`XBG",P3$5.D,^T6^?%06T2$:4=*02>
M57NJ\_+Z55>"=U@0N)'$J/,FQX[[MPYVT.N!)6$J<V1OOK8_-?3W+G?ZB;5<
M;&H/VC'8Q1)FM]6U.GG(0E0Z'JM/X50$GB659ID>;Y7COMUGC-V=U*!+3"6I
M1!*@-(+FMG0ZD]-=COI)VS-[Q9.(T?#\R$1]4]KQ;?<8K9:#O?W%H).CT(Z'
MT]:K'"ZZ0(''#B2S.F1X[K[Z"TEUP(Y^4JWK??6Q7]R%2,]X]XW_``!0DP,<
M3XTV8T>9M*^;F#84.A/1(U\SZ&@,[%=G]368<IT?X4WHG_VJFN&.97B\Y1F]
MKR%R"IJPOMM-O1V2T%))=VI0*E>2!^]5_$)<9?ZG<N"'VE%5M0@:6.JD^%L?
M4:._I6)PF]GNW$#C!#9DMGVU]*$*2H'8V^DJ'J`5#\T!:<0RK(>(:+C<<>D0
M[18V'U1XKC\8ONR5)[K(YDA*>O;O\ZRN&_$!V^'(;=D;,>'>+`ZI$PLD^$M`
MW_43OJ![IZ;/EZUKC@?9\;A1KCBV9PV(N10)*SRR72V7FCK2D=0%#OV\B*V(
MFPXI)@95:L+8BMW23`6Q(?C;4CF4E02E3G4<V^NM[T=T!A8AE.5<0S,NF/.V
M^RX\T\IF*N5%5(>E%/=1'.D)3^_EY5!<$O;?^USB/_%/`]M#C0=+&_#)VKJG
M?4"L_P#3E>X4+!/Y>N3S4&\6E]YN3%D*#:T[65!6CY==;^58'!JXPYG&?B.Y
M$E,O(?<0MI2%@AQ()!*?4?,4!O*M-\!?^]O$C_U3_P"1ZMQK4E"%*60E*1LD
MG0`K1G`V\VR-DW$%Z3<(C+3]RYVEN/)2'$\[QVG9ZCJ/S74LXN5I<872/_HU
MJS2JPS\?Z+CQ^C-R.%-Y4X`2SX3B"?)7B)'^Q-0BIKUPX`663))4ZI4!))\^
M66TG?[4XM7UK,+6G$,/=;N=PFNH]H6PKG:CM`\Q4M8Z#J!TJ3XA18.+<*(=K
M,AMMJ,[!905D)*^20TI1_"5*/WK:MTZ=*A2FO:=3*77&B\_P8IM2G.:VY<?4
MKO%&!)P+-H6?65M2H3ZPQ=6$#HH'0YOOKO\`Y`>M761.C7/.\0G074NQI$&6
MXVM/8@ANK5<X,*^V9^'+2B1!F-%"M'84E0[@_N#6B^&,&ZXUQ99Q2Y+4Y#MS
M,EZ$XH?$TYRGI\NGV/-5*,E=4&Y>_3B_K'#7W3\A-.E-)>[)KZ//Y-E<5WW)
M%I@8[%41*OLI,38[I9'O.J_T`C[U0KXPWP[XX6BX1DAFS7QL1'4@:2E7NI^V
MCR*^YJ<2S9^(W$NY)?E^/`L<9+#"(TI3:E.K)+BPI!!T``GTJ,XR\.;'"P2=
M<83DEF9"TZTN3.==!Z]4@+41LCMKKL"LUFZ=&4+6HVN98:Q_+;KT]GIW*U5*
M:=6/3;7M^LW95+XM9DO",4_B+#+;DAY]N,T7M^&@J/QKUUT`"=5Z<*<I9RS"
M[?,#R%S6VPU*0%>\AQ/39'EO6Q]:<2YV.MVR%:LMB+DP+O)3#2`C:4K/4*4K
M8Y>W<=:X5:E*C4=.>Z>#>A)3BI+J?RT.Y4F[VM9G6N]6.4TM4F2RV&2RK0*"
MC2U<Z3U^GK49=LTN-SSYS#\01%3*B-!^X3Y2"XW'2=:0E`(YEGF'F`/L:U\Q
MBSO#[BGC$/!K[*DP+D^H3;4MWQ0RR-<RSKIK1.B0#L=SNI*S+3@''G(7<@4(
M]KR1`<ASG.C?B`@^&5'H#U4/L/6L98O-NNV40<]:Q^Z1A<;:_#,A-V9B*90R
MX"1X:_>*2>@\P>HJ,X8YG>+SE.:VO('(*FK$\AMMZ.R6@H$N;4H%2O)`_>KV
MF^VI5P8@HN,5<Q\%3;*'`I2@!LG0[#YUIGA-[/=>(7%V&S);/MCP0A25`[&W
M4E0]0"10%JQ#*L@XAIN5PQZ1#M%CCOJCQ7'XQ?=DJ3K:R.9(2GJ.G?YUD<.<
MWN.4?S%9+BW%A9-9G5,.J;25LK[A+@22#K8.QOTZ]:USP0L^.08]RQ;-(;$;
M(H,E9"9+I;\9HZTI'4!0[]O+5;8Q.+A=LN]U_EEB&W*;:!FR(^U(`V3RK<V4
M\W3>M[UUH"G<+\ISG/;9<7C.LUM1#EKC>,B$MU3A`'9)<`2/GL[WY:J?X9YI
M=;OD>28UDC47^)V5:09,4%+;R%=CRDG1[>?G5:_2R^T[C.0I;<0I0NKB]!6S
MH@:/T.C6-PY>C2N//$IA$AO;[2$(Y5C9T`%:]=&@+1CF7WO/KI<U8H[#M^/P
M'C&]N?8+[DIP#9Y$\R0E(!'4[)V*SL=RZ[1FLK_G&`J-&L2BI%P2PIIN8T`H
ME2$DGJ.4=B1U':J7^GV:UAK5WPC)'&X%VC3%OL^,0A,EI02`I!/Q?#^#\JV#
MFZ8F98CDF/V>='?N"HBDE+;@4$+()0%$=!LC\4!!XK?,QS;&UY#:W[9:8SY6
M8$1^,IY3B4D@%Q?.-;(/8=/G7UAW%%%ZX<7C(9<$M3[.'43(C:MCQ$)W[I]#
M^W7TJH<%(.'3L19M=_B1HN16U2V)L>4ZIIS842%<I4.FB/O5UC3L&QC%,BFV
M:`ARSL'EG^Q,EQ#Q/ND`D\J]!6CHZ'G0&)C5_P`OR#&+7D%FFV2X*E.-J?MJ
M&^1++9/O)\3G)YTCOL=='I6T*YJS_"[9B5LB97PSO4JVW"2ZT8]N:?YQ)YR-
M)2G>SW^$['?M72$,NJB,*DI"7RA)<`[!6NO[T!ZTI2@*QQ,N-NM>#7>5>8S<
MJ&EDI+#@V'5'HE/Y(Z^7>N&B=DD`#Y"NJ_U1NN-\/(J&R>1RX-I7KTY%G_<"
MN4Z][Z,4E&UE4_D_Z.)Q&>:BCV1<\`S,8VEZ-+96]#=5SCD^)"NWGW%9&>YR
MF_Q$P8##C47F"UK<(YEZ[#0["J)2NH^%VSN/6G'VOSWP:WK-3P_#SH;/_3[E
M:<<S=N+(2W[+=.6,MPI]Y"M^X0?39T1\_E77U?GQ#=+,QAU*N4H<2H'TT=UV
M]!S_`!21&2M.1VHJ"`I23*0%=NO0G=>;])K-^+&M3BWE:X^&QT.'5DHN$GL6
M*;,C0(RY$V0U'CH&U..K"4I^I-5`\5,)$GP/YAB<^];TKE_U:U7+_%//I^;7
MQY:G7&[4TLB+&!TD)']Q'FH]]_:J162T]%XRIJ5Q)J3Z+H5J\2:EBFM#]!+=
M/B7**B3;Y3,J.OX7&5A:3]Q637$'#?.+CA5\9DQ77%05J`DQ=^ZXCSZ>2AY&
MNU(=RB3(;$EB0VIEYM+B#S#JDC8_8UQ.*\*GP^:6<Q>S-RVNE779HQ;ICEEN
MTE$BZ6F!+?0-)<?82M0'ILBOI^QVE4MB>Y:XBY<1.F'?`25M@=@DZZ?*I.E<
MDVC2'"C&7WLLS9658N\B%=)8F153F$+1H*7T[G2M+'[UN:#"B6V*F/;XK,:.
MCLTPV$)'T`K)I0&D>'6.R9/$G.).28O(%KN[R7HJYK"%(]PJ[C9T2%=*W);K
M?"MD81[=$CQ&!U#;#80G\"LJE`1K%@L\>9[7'M-O:E[4?&1&0E>R"#[P&^NS
MOZU_;?8K1;7R_;K7`B/%/*7&(Z&U$>FP-ZZ5(TH"-N]AM%YY#=K9"FE'PE]E
M*RGZ$BLJ!"BV^,F/`C,QHZ?A;90$)'V%9%*`B;IC5CNTA,BYVB!+?3T#CS"5
MJUZ;(KVBV2U1)GM<6V069>N7QFV$I7K6M<P&]:`%2%*`^7$(=;4VXE*T*!2I
M*AL$'N"*BAC%@!!%CM8(_P#"-_\`2O?(I4R%8I\JV1O:IK+*ELL_YJ`Z#Y_2
MJ_@.3-W]<E*;HF2ZTV@NQ78Q8D1W#OF"DG^WMKIY'J:V*=.KX;J0>BW_`'_)
MCE*/,HO<M42)&AM^'$CLL(_Q:0$C\"O*X6V#<DH3<84:6E!)2'VDN!)^6QTK
M7ZLPN]T3D+]GYD+MTAR-$C""X\)"F]<W.L=MG8`!&NYW4_D^4R+/AL2Z"%R7
M"8IAAN,]L!MUT@:7YZ3L[^E9':UHSBO^3>/B55:#3[(M++3;#*&F4(;:0D)0
MA`TE('8`#L*^%Q(SDE,E<=E4A*2A+I0"L)/<`]]?*HRW,WN/<T)FRHTN`IC:
MUAOPUH>V.B0.G(1OOLCUJ(LE\N$R^YE`?<:Y+6XTF,M+>B`MGG][KUT36-49
M/F<6M%G[O'Y+.:6$T6&!9K7;WB[`ML**Z1RE;+"4*(]-@5ZW.-!E0UINC$=^
M*C^HH2$!2!H=R#TZ=:IT#);E,X/#(RME%S_AZY6TM^YS)!.N4GMTJ3QV3=KA
MBJ[G<7V`J9#2^PREC7@`M[][9/,3L$CIKJ*O.C4BW.<MGC?7**JI%X26ZR2E
M@8LPA(EV"/!1%DI"P[$;2E+@\CM(ZUFSH<6X15QYT=F3'7\3;J`M)^QK7JKG
M*N'`:1<`6HTERUN+_H-\B4Z!^%([=!4BZ_>K=PH8F6I]IZYQH#;Z>=G86D)!
M*=;[\N^N^XJ\[63;S+7FY=?[R1&JL;=,EGM-CM5GY_X5;HD,K^(L,I05?4@=
M:R+A`B7**J-<(K$J.KNV\V%I/V-0=DO#UZG6YZWR4+MRH")+^V^JE.?\,`[Z
M=`LD?3UK+S.XS[5C<R;:8BI<QH)*6DH*SKF`40D:*B!LZ\]5KNA)35/J_P!U
M,G.L.70R;38K39T+1:K;#AI<Z+##*4<WUT.M+?8K1;9!?M]K@1'R"DN,1T-J
M(/EL#>JB,'R&/?8DQ^-=6Y[;2P.4L%EYGW>J7$^N]ZZ#[U!1,FOEUPVXY5!=
MC,QV"^Y'@K9Y@XTTI0/.O>PI7*=:Z#8Z&LBM*G,XO3#2U[O8KXT<)HM&4P\<
M>:8=R:-;G&_$#32YC:5>\KLD$CN:D6+7`CV\P6(45N$04F.EI(;(/<%.M51N
M(5Q;O/#:VW)I!0W*DP7DI5W3S.H.OWJ>RZ\3;5>L88B*;\"X3C%?2M&R4^&I
M0(.^AVG]ZE6K<5C?,O\`JDR/%67VT\R9MMGMEK+AMENAPRYKG,=A+?-KMOE`
MW7G%L-GB3/:XMJM[,O9/C-QD)7L]_>`WUJ+MMXF/9_>;.ZIM4.-$8D-:1I0*
MRL$$^8]VH?`O;%9UG1?E^(PB8T@-E'8^"@C1WT`'37GWJOJSQ)M[)/[X_P`D
M^*LI+J\?8L<J+CV4*?8E1[==%0G2TXEQM+A97W*3OL:DK=;X=MC)CVZ*Q%83
MV;9;"$_@56,+N;TB^9?'D)8"(4\(0IIH(4L%M*MJU\1ZZW\JB8F3WNZ87<,L
MA/168['CNL05L["VFE*!YU[V%*"3VZ#8Z&K.TES-+1:?=K*(598R_CY%PNN-
MV2[/I?NEH@2WD]`X\PE:OR14@U%CLQ1&:8:1'">4-)0`@#TUVU5+R[*IC6#6
MJ^V-3;*YCT4!+[?..5U0!!&QVWY>E9C%VN<'/(ECG269<>7!<DI<#/AK;6A0
M!'0Z*2%>?7IWJJM9\O-\]/EN3XT<X^7F2]OQFQVZ7[5`L]OC2?\`FM1TI4/H
M0.E2]:^RC+Y%IR=^!.EBSQ"AHPI;\4N1Y"S\86L?#KH`-CUW6P4G:0000?,5
M2I0E3C&4MGL6C44FTN@I2E82Y4N*N,JRS!KC;&0#*Y0['W_S$G8'WZC[UQ$^
MTXP\XR^A3;K:BE:%#121W!%?H57(''V;:[IQ'>9L,5'CMZ9DNM#_`([^^O3M
ML=!OS.Z];Z,7<U*5OC,=\]O]G*XE26%4Z[&L:5L67P8SF/R\MH2^E0!VU(;.
MM^1!(/[5-XQP$R:X2$&]J8M4;?O;6'7"/D$G7Y->EGQ2SA'G=58^>?+<YZMJ
MK>%%E+X;83-SF_&!$7X#+:"X])*>9+8\NGJ3TU5^O_Z?[M;+7,FQ[Q#DIC-+
M>\/PE)4H)!.AWZ]*Z$PO$K5AUH3;[,SR()YG'5]5NJ_R4?\`\!4^H!0(4`0>
MA!\Z\G=>DE>5?-#2'9I:G4I\/@H8GN?GE2MK\7^%-QQNZ2;A9HKLJQNJ*TEH
M<RH^^Z5`==#R/;5:IT=ZT=^E>SMKJE=4U4I/*?[J<BI3E3ERR1_*Z'QJTY$K
M';4IKQ0V8C12-'MR#54/A1PMN>6W-B5/CNQ;$VH*=><3REX#^U`/??;?85U^
MRTAAEMII(0VA(2E(&@`.@%><X]Q2%.4:5/$FM_@;]E:N2<I:(^Z4I7B3LBE*
M4`I2E`*4I0"E*4`I2E`8EVAJGVY^*W)?B+<3H/,*TM!WO8-8%ML*(U[D7>4\
M)%Q>93'\0-AL);!)UH=R2>Y)[#M4U2KJI*,7%/1E7%-Y96FL77!NLZ99;D[!
M1/<\:3'\)+B"YH`K3OX5'0WW!]*S[Y88=[L2[5<O%=84$_U"K^H%)(*5A7DH
M$`[J6I5G7J-J6=5UZZ$*G%)KN1=I@3XA3[==G)J4)Y4A3*$$_-1'<_30^51S
MV+*3>KK<+?<GHANB4"6@-I7LH3R!22?A/+T\Q5EI15IIMKK\%\]@X1:PRK1,
M0;BX`<51.>,?V=442"A/.$'OT[;T2*F(=L,7'FK6B0H^%&$9+Q2-Z">4*UVW
M4C2DJ\YYYGUS]0H16WR*W;\3CQ,&_E=R2\]$]G7&\4@!?*K?ITV-UD1TIQO&
MF&)SLF>TPE#',U&*U%/1(VA`)T/,U.4J77E+//JF\OYCD2V^16>'E@;Q['41
MT(<0775O\CAVIM*E$H0?_*GE3KY5,W>$Y.B!IB8]#=2M+B76CUVD[T1YI/8B
MLVE5G5E.HZCW>I*@E'EZ$/9;"U;;A<;@MSQI\\H\=SD"`0@:2`!]3U.SUJ(7
MA+:+;,M,.XOQK),6M3L1"$[2%G:T(7W2E1)Z==;.M5;Z597%1/*?;RV^W0AT
MXM8P5W)<68O./Q;0Q(7`BQW&EH\%`.@V04IZ^6P/Q61DM@1?&X"C)<C2H,A,
MJ.\@`\JP".J3T(()&JFJ5"KU%C#VSY[ATXO.A7+/C3D#)9M[D7-Z5)EL(8<0
MII*$`()*>774=SZU[6G'A;,AN]S8EN%NYK0Z['4@:"TH"-A7?6AVJ=I4NO4E
MG+W6/HO]!4XH@L>QU-FN=ZFB6X^NZ/B0XE:0`@A/+H:\M`=_2HU6$MHMLRTQ
M+B_&LDM:U.Q$(3M(6=K0A?=*5;/3KK9T15OI4JYJ)\V>WEM]B/"CC&"N9-BL
M>]6&):67UP8T9UIQOP4`Z#9VE/7RV!^*]I>.B1E\&_F8XER+&7&#`0.125'9
M)/??0?BIVE0KBHEA/OY[_<GPXMYQ^HKE[Q@WA%QC2KB^NVS^4/1EH"^4``$-
MJ/P`Z]-[V1JK"VA+;:4(&DI`2!Z`5]4JDJDI)1;T1*BD\H5K#-N-.-XU+<AQ
M_%NDULE*T1B.1!]"L]-_3=/U"95(QK"/!@.*:F7%SV=+B3HH1K:R/GKI]ZY!
M)V=GJ:])P3@D+N'CU_=Z+N<^\O)4I<D-SH6Y_J(3)LTYF'97HD];93'=+X<2
MA1Z<Q]T=N_UJN?ISQ!6096Y?;@DN0[<KG!7U\1\]1U/?7Q?75:=K:OZ=\KD6
M3-V+6MP_PZYGPEMGL'->XH?/?3Z'Y5W;KA\;.SJJS6&UKOMU\LFE3KNK5CXS
MRCKBE*5\[.^*4I0`C8T>U1QL=I,CQS:X!?WOQ#'1S;^NMU(TJRDX[,AI/<``
M``#0'D*4I5212E*`4I2@%*4H!2E*`4I2@%*4H!2E*`4I2@%*4H!2E*`4I2@%
M*4H!2E*`4I2@%*4H!2E*`4I2@%*4H#2'ZJ;6_)Q>U7!I)4U#D*2[K^T+``)^
MZ0/O7,-?H#>+9$O%KDV^XLI>B2$%#B%>8_Z^=<M9[P1O=B?>D693=PM>R4E3
MB6W&QZ*!(!^H_`KV?H]Q2C"EZM5>&GIG9Y.1?VTG+Q(K)J.KMP8MCUUXEV)M
MA)(9?$APC^U*/>)/X`^]>6.\-LFOTP1X4)M/7WEN/H"4_,]=_@5T[PGX;P\#
MM[BE.)E7:0`'Y'+H`?X(]!O\UTN+\5H6]"4(R3FUA)?'JS7M;:=2:;6B+_2E
0*^='?%*4H!2E*`4I2@/_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
